Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/08/23
Denali Therapeutics Reports First Quarter 2023 Financial Results and Business HighlightsGlobeNewsWire • 05/08/23
Denali Therapeutics Inc. (DNLI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 04/27/23
Denali Therapeutics: Pioneering The Neurodegenerative Space With Blood-Brain Barrier InnovationsSeeking Alpha • 04/17/23
Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid BetaGlobeNewsWire • 04/12/23
Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual MeetingGlobeNewsWire • 04/10/23
Why Is Denali Therapeutics Inc. (DNLI) Down 16% Since Last Earnings Report?Zacks Investment Research • 03/29/23
Denali Therapeutics Inc. (DNLI) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/27/23
Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business HighlightsGlobeNewsWire • 02/27/23
Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™GlobeNewsWire • 02/22/23
Earnings Preview: Denali Therapeutics Inc. (DNLI) Q4 Earnings Expected to DeclineZacks Investment Research • 02/20/23
Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™GlobeNewsWire • 02/15/23
Denali Therapeutics Inc. (DNLI) Surges 5.8%: Is This an Indication of Further Gains?Zacks Investment Research • 02/03/23
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by SanofiGlobeNewsWire • 01/25/23
Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage DiseasesGlobeNewsWire • 01/09/23
Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform TrialGlobeNewsWire • 12/05/22
Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business HighlightsGlobeNewsWire • 11/03/22